Merck Announces Increased Quarterly Dividend

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the Board of Directors has increased the company's quarterly dividend to $0.47 per outstanding share of the company's common stock, up $0.01 from $0.46 per outstanding share paid last quarter. Payment will be made on Jan. 9, 2017, to stockholders of record at the close of business on Dec. 15, 2016.

"We are making strides toward our overarching goal of bringing forward medicines and vaccines that create value for society and shareholders alike," said Kenneth C. Frazier, chairman and chief executive officer, Merck. "The dividend increase reflects our confidence in our innovation strategy and our commitment to returning meaningful value to our shareholders."

Merck last announced a dividend increase in November 2015, when the Board raised the dividend from $0.45 to $0.46 per common share.

About Merck

For 125 years, Merck has been a global health care leader working to help the world be well. Merck is known as MSD outside the United States and Canada. Through our prescription medicines, vaccines, biologic therapies, and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to health care through far-reaching policies, programs and partnerships. For more information, visit www.merck.com and connect with us on Twitter, Facebook, YouTube and LinkedIn.

Forward-Looking Statement of Merck & Co., Inc., Kenilworth, N.J., USA

This news release of Merck & Co., Inc., Kenilworth, N.J., USA (the "company") includes "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company's management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline products that the products will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

If you liked this article you might like

'Date' These Potential Biotech Winners

'Date' These Potential Biotech Winners

The 10 Stocks America's Biggest Hedge Funds Are Dumping Like Crazy

Why You Keep Cash on Hand; No Downside Conviction -- Jim Cramer's Top Thoughts